EDITOR'S NOTE: This is the first of a series of articles focusing on companies in Newburyport's business park. The series intends to show the kinds of businesses, innovations and job opportunities that are emerging as the park strives to compete in the global economy.
NEWBURYPORT — The industrial park here was founded decades ago, but today, numerous companies in the current business park are focused on high-tech solutions that are filling modern technical needs of companies around the country.
One such business is PCI Synthesis, a privately held enterprise that is involved in chemical manufacturing for biotech and pharmaceutical companies.
At 9 Opportunity Way, it is currently running three shifts and is recruiting qualified technical staff all the time.
PCI Synthesis is a 12-year-old custom chemical manufacturer of new chemical entities, generic active pharmaceutical ingredients and other specialty chemical products.
A contract manufacturing organization, PCI provides emerging and midsized pharmaceutical companies access "to the expertise needed to develop and manufacture complex small molecules and APIs used in generic pharmaceuticals."
Though he is in a very competitive market, PCI President Ed Price has found a way to create and sell quality products.
"Outsourcing by pharmaceutical companies (to companies like us) has been increasing," Price said. "We can help them for an early-stage idea to commercialization.
"We're in a good position here in Newburyport, being in the backyard of Boston-Cambridge, which has many pharma and biotech firms."
PCI employs about 95 in highly technical positions. It maintains a research and development arm in Devens, which has about 33 workers.
In recent months, PCI announced a collaboration deal with Biogen Idec, a public company that started in Cambridge and is considered one of the most prominent biotech operations in the country.
Part of PCI's role with Biogen Idec is to "evaluate and optimize a number of new compounds with the goal of identifying potential new drugs."